Cargando…
Serum Exosomal microRNA-21, 222 and 124-3p as Noninvasive Predictive Biomarkers in Newly Diagnosed High-Grade Gliomas: A Prospective Study
SIMPLE SUMMARY: Diagnosis of relapse during post-surgery monitoring of patients with High-grade glioma is often challenging. This study was aimed to identify circulating biomarkers providing information about response to therapy and early diagnosis of progression during follow-up of these patients....
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232769/ https://www.ncbi.nlm.nih.gov/pubmed/34203979 http://dx.doi.org/10.3390/cancers13123006 |
_version_ | 1783713708913983488 |
---|---|
author | Olioso, Debora Caccese, Mario Santangelo, Alessandra Lippi, Giuseppe Zagonel, Vittorina Cabrini, Giulio Lombardi, Giuseppe Dechecchi, Maria Cristina |
author_facet | Olioso, Debora Caccese, Mario Santangelo, Alessandra Lippi, Giuseppe Zagonel, Vittorina Cabrini, Giulio Lombardi, Giuseppe Dechecchi, Maria Cristina |
author_sort | Olioso, Debora |
collection | PubMed |
description | SIMPLE SUMMARY: Diagnosis of relapse during post-surgery monitoring of patients with High-grade glioma is often challenging. This study was aimed to identify circulating biomarkers providing information about response to therapy and early diagnosis of progression during follow-up of these patients. Our findings, showing upregulation of exosomal miRNAs associated with relapse represent a proof of principle that these biomarkers may be clinically useful tools for diagnosing and monitoring of gliomas. ABSTRACT: Background: High-grade gliomas (HGG) are malignant brain tumors associated with frequent recurrent disease. Clinical management of HGG patients is currently devoid of blood biomarkers for early diagnosis, monitoring therapeutic effects and predicting recurrence. Different circulating miRNAs, both free and associated with exosomes, are described in patients with HGG. We previously identified miR-21, miR-222 and miR-124-3p purified from serum exosomes as molecular signature to help pre-operative clinical diagnosis and grading of gliomas. The aim of the present study was to verify this signature as a tool to assess the effect of treatment and for the early identification of progression in newly diagnosed HGG patients. Material and Methods: Major inclusion criteria were newly diagnosed, histologically confirmed HGG patients, no prior chemotherapy, ECOG PS 0-2 and patients scheduled for radiochemotherapy with temozolomide as first-line treatment after surgery. RANO criteria were used for response assessment. Serum was collected at baseline and subsequently at each neuroradiological assessment. mir-21, -222 and -124-3p expression in serum exosomes was measured in all samples. Results: A total number of 57 patients were enrolled; 41 were male, 52 with glioblastoma and 5 with anaplastic astrocytoma; 18 received radical surgery. HGG patients with higher exosomal miRNA expression displayed a statistically significant lower progression-free survival and overall survival. Increased expression of miR-21, -222 and -124-3p during post-operative follow-up was associated with HGG progression. Conclusions: These data indicate that miR-21, -222 and -124-3p in serum exosomes may be useful molecular biomarkers for complementing clinical evaluation of early tumor progression during post-surgical therapy in patients with HGG. |
format | Online Article Text |
id | pubmed-8232769 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82327692021-06-26 Serum Exosomal microRNA-21, 222 and 124-3p as Noninvasive Predictive Biomarkers in Newly Diagnosed High-Grade Gliomas: A Prospective Study Olioso, Debora Caccese, Mario Santangelo, Alessandra Lippi, Giuseppe Zagonel, Vittorina Cabrini, Giulio Lombardi, Giuseppe Dechecchi, Maria Cristina Cancers (Basel) Article SIMPLE SUMMARY: Diagnosis of relapse during post-surgery monitoring of patients with High-grade glioma is often challenging. This study was aimed to identify circulating biomarkers providing information about response to therapy and early diagnosis of progression during follow-up of these patients. Our findings, showing upregulation of exosomal miRNAs associated with relapse represent a proof of principle that these biomarkers may be clinically useful tools for diagnosing and monitoring of gliomas. ABSTRACT: Background: High-grade gliomas (HGG) are malignant brain tumors associated with frequent recurrent disease. Clinical management of HGG patients is currently devoid of blood biomarkers for early diagnosis, monitoring therapeutic effects and predicting recurrence. Different circulating miRNAs, both free and associated with exosomes, are described in patients with HGG. We previously identified miR-21, miR-222 and miR-124-3p purified from serum exosomes as molecular signature to help pre-operative clinical diagnosis and grading of gliomas. The aim of the present study was to verify this signature as a tool to assess the effect of treatment and for the early identification of progression in newly diagnosed HGG patients. Material and Methods: Major inclusion criteria were newly diagnosed, histologically confirmed HGG patients, no prior chemotherapy, ECOG PS 0-2 and patients scheduled for radiochemotherapy with temozolomide as first-line treatment after surgery. RANO criteria were used for response assessment. Serum was collected at baseline and subsequently at each neuroradiological assessment. mir-21, -222 and -124-3p expression in serum exosomes was measured in all samples. Results: A total number of 57 patients were enrolled; 41 were male, 52 with glioblastoma and 5 with anaplastic astrocytoma; 18 received radical surgery. HGG patients with higher exosomal miRNA expression displayed a statistically significant lower progression-free survival and overall survival. Increased expression of miR-21, -222 and -124-3p during post-operative follow-up was associated with HGG progression. Conclusions: These data indicate that miR-21, -222 and -124-3p in serum exosomes may be useful molecular biomarkers for complementing clinical evaluation of early tumor progression during post-surgical therapy in patients with HGG. MDPI 2021-06-15 /pmc/articles/PMC8232769/ /pubmed/34203979 http://dx.doi.org/10.3390/cancers13123006 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Olioso, Debora Caccese, Mario Santangelo, Alessandra Lippi, Giuseppe Zagonel, Vittorina Cabrini, Giulio Lombardi, Giuseppe Dechecchi, Maria Cristina Serum Exosomal microRNA-21, 222 and 124-3p as Noninvasive Predictive Biomarkers in Newly Diagnosed High-Grade Gliomas: A Prospective Study |
title | Serum Exosomal microRNA-21, 222 and 124-3p as Noninvasive Predictive Biomarkers in Newly Diagnosed High-Grade Gliomas: A Prospective Study |
title_full | Serum Exosomal microRNA-21, 222 and 124-3p as Noninvasive Predictive Biomarkers in Newly Diagnosed High-Grade Gliomas: A Prospective Study |
title_fullStr | Serum Exosomal microRNA-21, 222 and 124-3p as Noninvasive Predictive Biomarkers in Newly Diagnosed High-Grade Gliomas: A Prospective Study |
title_full_unstemmed | Serum Exosomal microRNA-21, 222 and 124-3p as Noninvasive Predictive Biomarkers in Newly Diagnosed High-Grade Gliomas: A Prospective Study |
title_short | Serum Exosomal microRNA-21, 222 and 124-3p as Noninvasive Predictive Biomarkers in Newly Diagnosed High-Grade Gliomas: A Prospective Study |
title_sort | serum exosomal microrna-21, 222 and 124-3p as noninvasive predictive biomarkers in newly diagnosed high-grade gliomas: a prospective study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232769/ https://www.ncbi.nlm.nih.gov/pubmed/34203979 http://dx.doi.org/10.3390/cancers13123006 |
work_keys_str_mv | AT oliosodebora serumexosomalmicrorna21222and1243pasnoninvasivepredictivebiomarkersinnewlydiagnosedhighgradegliomasaprospectivestudy AT caccesemario serumexosomalmicrorna21222and1243pasnoninvasivepredictivebiomarkersinnewlydiagnosedhighgradegliomasaprospectivestudy AT santangeloalessandra serumexosomalmicrorna21222and1243pasnoninvasivepredictivebiomarkersinnewlydiagnosedhighgradegliomasaprospectivestudy AT lippigiuseppe serumexosomalmicrorna21222and1243pasnoninvasivepredictivebiomarkersinnewlydiagnosedhighgradegliomasaprospectivestudy AT zagonelvittorina serumexosomalmicrorna21222and1243pasnoninvasivepredictivebiomarkersinnewlydiagnosedhighgradegliomasaprospectivestudy AT cabrinigiulio serumexosomalmicrorna21222and1243pasnoninvasivepredictivebiomarkersinnewlydiagnosedhighgradegliomasaprospectivestudy AT lombardigiuseppe serumexosomalmicrorna21222and1243pasnoninvasivepredictivebiomarkersinnewlydiagnosedhighgradegliomasaprospectivestudy AT dechecchimariacristina serumexosomalmicrorna21222and1243pasnoninvasivepredictivebiomarkersinnewlydiagnosedhighgradegliomasaprospectivestudy |